JWJennifer S. Weizer

Jennifer S. Weizer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jennifer S. Weizer has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safety Outcomes Following Implementation of a Systematic Cataract Surgery Protocol at a Tertiary Referral Eye Center

    by Joshua Ong, Beth K. Hansemann, Paul P. Md Lee, Jennifer S. Weizer

    Purpose: To evaluate the longitudinal safety outcomes of incorrect intraocular lens (IOL) implantation using a standardized cataract surgery operating standard operating procedure (SOP) devised at a tertiary referral eye center. This evaluation represents a critical but underrepresented topic in ophthalmic literature. Methods: This was a quality improvement, retrospective analysis, and description of the Healthcare Failure Mode Effect and Analysis (HFMEA) and resultant SOP implemented in 2018 following incorrect IOL events. Analysis of subsequent safety events following implementation of the SOP and modifications/reassessments performed was analyzed. The main outcome measures were processes identified in the HFMEA and incorrect IOL safety events occurring following implementation of the SOP. Results: The HFMEA identified 170 processes/subprocesses steps, 177 potential failure modes, and 75 potential failure mode causes. Twenty-nine system vulnerabilities were identified through analysis of the failure mode causes. From 2018 to 2023, 8 additional incorrect IOL safety events occurred, which led to subsequent revisions of the SOP. Conclusion: Continuous reassessment of standardized protocols for cataract surgery is critical to ensure patient safety.


  • Reliability of Intraocular Pressure Measurements in a Low-Contact Drive-Through Setting

    by Lynn W. Sun, Yunshu Zhou, Joshua D. Stein, Jennifer S. Weizer

    Précis: Drive-through IOP measurement using iCare tonometry is a promising method of low-contact, high-throughput IOP monitoring. However, owing to its vulnerability to variable measurement technique and local air currents, the iCare may overestimate IOPs. Purpose: During the COVID-19 pandemic, a drive-through intraocular pressure (IOP) measurement protocol using the iCare tonometer was established to facilitate low-contact monitoring of select glaucoma patients.1 As the iCare may be prone to error due to variable measurement technique and local air currents,2 we endeavored to assess the reliability of drive-through IOP measurements by comparing them with recent measurements taken in clinic settings. Methods: Inclusion criteria were patients with drive-through IOP measurements performed from Apr 28-Oct 11, 2020; exclusion criteria were pre-drive-through IOPs >21 mmHg. Drive-through IOP measurements were compared with the closest previous and/or subsequent in-clinic IOP measurements. Data was gathered using the Sight Outcomes Research Collaborative (SOURCE) data repository.3 Results: The post-exclusion study group consisted of 314 patients receiving a total of 868 drive-through IOP measurements, all of whom had prior in-clinic measurements, and 56.8% of whom had subsequent in-clinic measurements. Drive-through IOPs were, on average, +2.4 mmHg (+14.5%; SD 4.9) higher than in-clinic IOPs. Further sub-analysis of the data showed a difference of +2.1 mmHg OD and +2.6 mmHg OS. Compared to the closest previous in-clinic visit, the difference was +2.4 mmHg OU (+2.1 mmHg OD, +2.7 mmHg OS); compared to the closest subsequent in-clinic visit, the difference was +2.3 mmHg OU (+2.1 mmHg OD, +2.5 mmHg OS). 68.6% of all drive-through IOPs were higher than corresponding in-clinic IOPs; 21.1% were lower. 25.9% of drive-through IOPs were higher by more than 5 mmHg, while 3.9% of drive-through IOPs were lower by more than 5 mmHg. Discussion: As teleophthalmology becomes an ever more important tool in glaucoma patient care, drive-through or walk-through IOP monitoring methods are likely to play an increasing role. However, our data reveals potential inaccuracies in drive-through iCare IOP measurements which tend to overestimate IOP. It is advisable to confirm large changes in IOP with in-clinic measurement prior to making management decisions. Conclusion: With better optimization of accuracy and reliability of measurements, drive-through tonometry is a promising, high-throughput, low-contact method of measuring IOP.


  • Electronic Health Records Are Here to Stay

    by Jennifer S. Weizer, Joshua R. Ehrlich, Paul P. Lee

    Ophthalmologists in the United States are adopting electronic health record (EHR) systems at an ever-increasing rate. As shown in the study by Lim et al1 in this issue of JAMA Ophthalmology, ophthalmologists have almost quadrupled their EHR use, from 19% in 2008 to 72% in 2016.1 Ophthalmology is not alone in seeking to understand the effect of EHRs on patient care and the workforce. The effects of EHR implementation have been the subject of numerous articles in the popular press, blog sites, and the scientific literature.2,3


  • Open Access

    Implementation of a Standardized Patient Safety Checklist in Ophthalmic Surgery

    by Erin A. Boese, Paul P. Lee, Grant M. Greenberg, Richard V. Harrison, Jennifer S. Weizer

    Objective To develop and institute a standardized ophthalmology-specific operating room checklist, and to test adherence to the surgical checklist components after implementation. Design An ophthalmology-specific operative room checklist was developed using recommendations from surgical preoperative checklists from other subspecialties and checklists specific to cataract surgery. This standardized checklist was then implemented into the operating rooms. Operative room staff was trained on its use. Adherence to the checklist was measured prospectively. Setting Surgical centers at Kellogg Eye Center in Ann Arbor and Livonia, Michigan. Participants Patients undergoing ophthalmic surgery at the Livonia and Ann Arbor surgical centers. Main Outcome(s) and Measure(s) The primary outcome measures were surgical team adherence to each category of the operative checklist (preop, prebrief, preanesthesia verification, time-out, intraocular lens measurement/confirmation for cataract cases, debrief). Adherence to the subsections of the operative checklist was measured during three periods over the course of 1 year: baseline, postintervention (after introduction of the checklist in all operating rooms), and postadjustment (after additional training was provided to operating room staff and incentives to collect data were provided to personnel responsible for collecting it). Results A total of 2,532 surgical cases were included in the analysis. Baseline adherence ranged from 87 to 90% across preop, prebrief, preanesthesia, and time-out verification sections of the operative checklist. After the institution of the intervention and adjustments, adherence to the surgical checklist improved significantly across all areas of the checklist to 97–98% (p < 0.01). Conclusions and Relevance The development and implementation of an ophthalmology-specific operative room checklist increase adherence to recommended safety checks prior to the start of surgery. To maximize patient safety, the same or similar checklist is recommended for use in all ophthalmology operating rooms. None.


  • Open Access

    Mapping standard ophthalmic outcome sets to metrics currently reported in eight eye hospitals

    by Monica Michelotti, Dirk F. de Korne, Jennifer S. Weizer, Paul P. Lee, Declan Flanagan, Simon P. Kelly, Anne Odergren, Sukhpal S. Sandhu, Charity Wai, Niek Klazinga, et al.

    To determine alignment of proposed international standard outcomes sets for ophthalmic conditions to metrics currently reported by eye hospitals. Mixed methods comparative benchmark study, including eight eye hospitals in Australia, India, Singapore, Sweden, U.K., and U.S. All are major international tertiary care and training centers in ophthalmology. Main outcome measure is consistency of ophthalmic outcomes measures reported. International agreed standard outcomes (ICHOM) sets are available for cataract surgery (10 metrics) and macular degeneration (7 metrics). The eight hospitals reported 22 different metrics for cataract surgery and 2 for macular degeneration, which showed only limited overlap with the proposed ICHOM metrics. None of the hospitals reported patient reported visual functioning or vision-related quality of life outcomes measures (PROMs). Three hospitals (38%) reported rates for uncomplicated cataract surgeries only. There was marked variation in how and at what point postoperatively visual outcomes following cataract, cornea, glaucoma, strabismus and oculoplastics procedures were reported. Seven (87.5%) measured post-operative infections and four (50%) measured 30 day unplanned reoperation rates. Outcomes reporting for ophthalmic conditions currently widely varies across hospitals internationally and does not include patient-reported outcomes. Reaching consensus on measures and consistency in data collection will allow meaningful comparisons and provide an evidence base enabling improved sharing of “best practices” to improve eye care globally. Implementation of international standards is still a major challenge and practice-based knowledge on measures should be one of the inputs of the international standardization process.


  • Establishing a Regional Glaucoma Physician Collaborative to Improve Quality of Care

    by Joshua R. Ehrlich, Jeffrey N. Wentzloff, Nauman R. Imami, Taylor S. Blachley, Joshua D. Stein, Paul P. Lee, Jennifer S. Weizer


  • Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty

    by Linda Zhang, Jennifer S Weizer, David C Musch

    Glaucoma is the international leading cause of irreversible blindness. Intraocular pressure (IOP) is the only currently known modifiable risk factor; it can be reduced by medications, incisional surgery, or laser trabeculoplasty (LTP). LTP reduces IOP by 25% to 30% from baseline, but early acute IOP elevation after LTP is a common adverse effect. Most of these IOP elevations are transient, but temporarily elevated IOP may cause further optic nerve damage, worsening of glaucoma requiring additional therapy, and permanent vision loss. Antihypertensive prophylaxis with medications such as acetazolamide, apraclonidine, brimonidine, dipivefrin, pilocarpine, and timolol have been recommended to blunt and treat the postoperative IOP spike and associated pain and discomfort. Conversely, other researchers have observed that early postoperative IOP rise happens regardless of whether people receive perioperative glaucoma medications. It is unclear whether perioperative administration of antiglaucoma medications may be helpful in preventing or reducing the occurrence of postoperative IOP elevation. To assess the effectiveness of medications administered perioperatively to prevent temporarily increased intraocular pressure (IOP) after laser trabeculoplasty (LTP) in people with open-angle glaucoma (OAG). We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 11), MEDLINE Ovid (1946 to 18 November 2016), Embase.com (1947 to 18 November 2016), PubMed (1948 to 18 November 2016), LILACS (Latin American and Caribbean Health Sciences Literature Database) (1982 to 18 November 2016), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com); last searched 17 September 2013, ClinicalTrials.gov (www.clinicaltrials.gov); searched 18 November 2016 and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en); searched 18 November 2016. We did not use any date or language restrictions. We included randomized controlled trials (RCTs) in which participants with OAG received LTP. We included trials which compared any antiglaucoma medication with no medication, one type of antiglaucoma medication compared with another type of antiglaucoma medication, or different timings of medication. Two review authors independently screened records retrieved by the database searches, assessed the risk of bias, and abstracted data. We graded the certainty of the evidence using GRADE. We included 22 trials that analyzed 2112 participants and identified no ongoing trials. We performed several comparisons of outcomes: one comparison of any antiglaucoma medication versus no medication or placebo, three comparisons of one antiglaucoma medication versus a different antiglaucoma mediation, and one comparison of antiglaucoma medication given before LTP to the same antiglaucoma medication given after LTP. Only one of the included trials used selective laser trabeculoplasty (SLT); the remaining trials used argon laser trabeculoplasty (ALT). Risk of bias issues were primarily in detection bias, reporting bias, and other potential bias due to studies funded by industry. Two potentially relevant studies are awaiting classification due to needing translation. In the comparison of any medication versus no medication/placebo, there was moderate-certainty evidence that the medication group had a lower risk of IOP increase of 10 mmHg or greater within two hours compared with the no medication/placebo group (risk ratio (RR) 0.05, 95% confidence interval (CI) 0.01 to 0.20). This trend favoring medication continued between two and 24 hours, but the evidence was of low and very low-certainty for an IOP increase of 5 mmHg or greater (RR 0.17, 95% CI 0.09 to 0.31) and 10 mmHg or greater (RR 0.22, 95% CI 0.11 to 0.42). Medication was favored over placebo/no medication with moderate-certainty in reducing IOP from the pre-LTP measurements for both within two hours and between two and 24 hours. At two hours, the mean difference (MD) in IOP between the medication group and the placebo/no medication group was -7.43 mmHg (95% CI -10.60 to -4.27); at between two and 24 hours, the medication group had a mean reduction in IOP of 5.32 mmHg more than the mean change in the placebo/no medication group (95% CI -7.37 to -3.28). Conjunctival blanching was an ocular adverse effect that was more common when brimonidine was given perioperatively compared with placebo in three studies. In our comparison of brimonidine versus apraclonidine, neither medication resulted in a lower risk of increased IOP of 5 mmHg or greater two hours of surgery; however, we were very uncertain about the estimate. There may be a greater mean decrease in IOP within two hours after LTP. We were unable to perform any meta-analyses for other review outcomes for this comparison. In our comparison of apraclonidine versus pilocarpine, we had insufficient data to perform meta-analyses to estimate effects on either of the primary outcomes. There was moderate-certainty evidence that neither medication was favored based on the mean change in IOP measurements from pre-LTP to two hours after surgery. In the comparison of medication given before LTP versus the same medication given after LTP, we had insufficient data for meta-analysis of IOP increase within two hours. For the risk of IOP increase of 5 mmHg or greater and 10 mmHg or greater at time points between two and 24 hours, there was no advantage of medication administration before or after LTP regarding the proportion of participants with an IOP spike (5 mmHg or greater: RR 0.82, 95% CI 0.25 to 2.63; 10 mmHg or greater: RR 1.55, 95% CI 0.19 to 12.43). For an IOP increase of 10 mmHg or greater, we had very low-certainty in the estimate, it would likely change with data from new studies. Perioperative medications are superior to no medication or placebo to prevent IOP spikes during the first two hours and up to 24 hours after LTP, but some medications can cause temporary conjunctival blanching, a short-term cosmetic effect. Overall, perioperative treatment was well tolerated and safe. Alpha-2 agonists are useful in helping to prevent IOP increases after LTP, but it is unclear whether one medication in this class of drugs is better than another. There was no notable difference between apraclonidine and pilocarpine in the outcomes we were able to assess. Future research should include participants who have been using these antiglaucoma medications for daily treatment of glaucoma before LTP was performed. Fármacos perioperatorios para la prevención del aumento temporal de la presión intraocular después de la trabeculoplastia con láser El glaucoma es la principal causa de ceguera irreversible en todo el mundo. La presión intraocular (PIO) es el único factor de riesgo modificable actualmente conocido; se puede reducir mediante fármacos, cirugía incisional o trabeculoplastia con láser. La trabeculoplastia con láser reduce la PIO del 25% al 30% a partir del valor inicial, pero la elevación aguda temprana de la PIO después de la trabeculoplastia con láser es un efecto adverso frecuente. La mayoría de estas elevaciones de la PIO son transitorias, pero la elevación temporaria de la PIO puede provocar daño adicional en el nervio óptico, empeoramiento del glaucoma que requiere tratamiento adicional y pérdida permanente de la visión. La profilaxis antihipertensiva con fármacos como la acetazolamida, la apraclonidina, la brimonidina, la dipivefrina, la pilocarpina y el timolol se ha recomendado para reducir y tratar el pico posoperatorio de la PIO y el dolor y el malestar asociados. Por el contrario, otros investigadores han observado que la elevación posoperatoria temprana de la PIO ocurre independientemente de si los pacientes reciben fármacos perioperatorios para el glaucoma. No está claro si la administración perioperatoria de los fármacos antiglaucoma puede ser útil para prevenir o reducir la ocurrencia de la elevación posoperatoria de la PIO. Evaluar la efectividad de los fármacos administrados perioperatoriamente para prevenir el aumento temporal de la presión intraocular (PIO) después de la trabeculoplastia con láser en los pacientes con glaucoma de ángulo abierto (GAA). Se hicieron búsquedas en CENTRAL (que contiene el registro de ensayos del Grupo Cochrane de Trastornos de los Ojos y la Visión [Cochrane Eyes and Vision Group]) (2016, número 11), MEDLINE Ovid (1946 hasta 18 noviembre 2016), Embase.com (1947 hasta 18 noviembre 2016), PubMed (1948 hasta 18 noviembre 2016), LILACS (Latin American and Caribbean Health Sciences Literature Database) (1982 hasta 18 noviembre 2016), el metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com); última búsqueda 17 septiembre 2013, ClinicalTrials.gov (www.clinicaltrials.gov); búsqueda 18 noviembre 2016 y en la WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en); búsqueda 18 noviembre 2016. No se aplicó ninguna restricción de fecha ni de idioma. Se incluyeron los ensayos controlados aleatorios (ECA) en los que los pacientes con GAA recibieron trabeculoplastia con láser. Se incluyeron los ensayos que compararon cualquier fármaco antiglaucoma con ningún fármaco, un tipo de fármaco antiglaucoma comparado con otro tipo de fármaco antiglaucoma o diferentes momentos de administración del fármaco. Dos autores de la revisión revisaron de forma independiente los registros recuperados mediante las búsquedas en las bases de datos, evaluaron el riesgo de sesgo y resumieron los datos. La certeza de las pruebas se evaluó mediante GRADE. Se incluyeron 22 ensayos que analizaron a 2112 participantes y no se identificaron ensayos en curso. Se realizaron varias comparaciones de resultados: una comparación de cualquier fármaco antiglaucoma versus ningún fármaco o placebo, tres comparaciones de un fármaco antiglaucoma versus un fármaco antiglaucoma diferente y una comparación de un fármaco antiglaucoma administrado antes de la trabeculoplastia con láser con el mismo fármaco antiglaucoma administrado después de la trabeculoplastia con láser. Solo uno de los ensayos incluidos utilizó la trabeculoplastia con láser selectiva; los ensayos restantes utilizaron la trabeculoplastia con láser argón. Los problemas del riesgo de sesgo estuvieron principalmente en el sesgo de detección, el sesgo de informe y otro posible sesgo debido a los estudios patrocinados por la industria. Dos estudios potencialmente relevantes están en espera de clasificación debido a la necesidad de traducción. En la comparación de cualquier fármaco versus ningún fármaco/placebo, hubo pruebas de confiabilidad moderada de que el grupo del fármaco tuvo un riesgo menor de un aumento de la PIO de 10 mmHg o mayor en el transcurso de dos horas en comparación con el grupo de ningún fármaco/placebo (cociente de riesgos [CR] 0,05; intervalo de confianza [IC] del 95%: 0,01 a 0,20). Esta tendencia que favoreció al fármaco permaneció entre dos y 24 horas, pero las pruebas fueron poco y muy poco confiables para un aumento de la PIO de 5 mmHg o mayor (CR 0,17; IC del 95%: 0,09 a 0,31) y de 10 mmHg o mayor (CR 0,22; IC del 95%: 0,11 a 0,42). El fármaco fue mejor que placebo/ningún fármaco, con pruebas de confiabilidad moderada en la reducción de la PIO a partir de las mediciones previas a la trabeculoplastia con láser en el transcurso de dos horas y entre dos y 24 horas. A las dos horas, la diferencia de medias (DM) en la PIO entre el grupo del fármaco y el grupo placebo/ningún fármaco fue -7,43 mmHg (IC del 95%: -10,60 a -4,27); entre las dos y las 24 horas, el grupo del fármaco tuvo una reducción media de la PIO de 5,32 mmHg más que el cambio medio en el grupo placebo/ningún fármaco (IC del 95%: -7,37 a -3,28). En tres estudios el blanqueo conjuntival fue un efecto adverso ocular, que fue más frecuente cuando la brimonidina se administró perioperatoriamente en comparación con placebo. En la comparación de la brimonidina versus la apraclonidina, ningún fármaco dio lugar a un menor riesgo de aumento de la PIO de 5 mmHg o mayor a las dos horas de la cirugía; sin embargo, no hay seguridad con respecto al cálculo. Puede haber una mayor disminución media en la PIO en el transcurso de las dos horas después de la trabeculoplastia con láser. No fue posible realizar metanálisis de otros resultados de la revisión para esta comparación. En la comparación de la apraclonidina versus la pilocarpina no se obtuvieron suficientes datos para realizar los metanálisis para calcular los efectos sobre cualquiera de los resultados primarios. Hubo pruebas de confiabilidad moderada de que ningún fármaco fue mejor sobre la base del cambio medio en las mediciones de la PIO previas a la trabeculoplastia con láser hasta dos horas después de la cirugía. En la comparación del fármaco administrado antes de la trabeculoplastia con láser versus el mismo fármaco administrado después de la trabeculoplastia con láser, no hay suficientes datos para el metanálisis del aumento de la PIO en el transcurso de dos horas. Para el riesgo de un aumento de la PIO de 5 mmHg o mayor y de 10 mmHg o mayor en puntos temporales entre dos y 24 horas no hubo una ventaja del fármaco administrado antes o después de la trabeculoplastia con láser con respecto a la proporción de participantes con un pico de la PIO (5 mmHg o mayor: CR 0,82; IC del 95%: 0,25 a 2,63; 10 mmHg o mayor: CR 1,55; IC del 95%: 0,19 a 12,43). Para un aumento de la PIO de 10 mmHg o mayor hubo muy poca confiabilidad en el cálculo, que es probable que cambie con los datos de nuevos estudios. Los fármacos perioperatorios son superiores a ningún fármaco o placebo para prevenir los picos de la PIO durante las primeras dos horas y hasta 24 horas después de la trabeculoplastia con láser, pero algunos fármacos pueden provocar blanqueo conjuntival temporal, un efecto cosmético a corto plazo. En general, el tratamiento perioperatorio fue bien tolerado y seguro. Los agonistas alfa-2 son útiles para ayudar a prevenir los aumentos de la PIO después de la trabeculoplastia con láser, pero no está claro si un fármaco de esta clase es mejor que otro. No hubo diferencias notables entre la apraclonidina y la pilocarpina en los resultados que fue posible evaluar. Los estudios de investigación futuros deben incluir participantes que hayan utilizado estos fármacos antiglaucoma para el tratamiento diario del glaucoma antes de que se les realizara la trabeculoplastia con láser.


  • A Two-Year Longitudinal Assessment of Ophthalmologists’ Perceptions after Implementing an Electronic Health Record System

    by Joshua R. Ehrlich, Monica Michelotti, Taylor S. Blachley, Kai Zheng, Mick P. Couper, Grant M. Greenberg, Sharon Kileny, Greta L. Branford, David A. Hanauer, Jennifer S. Weizer

    Summary: Objectives To understand the attitudes and perceptions of ophthalmologists toward an electronic health record (EHR) system, before and after its clinical implementation.Methods Ophthalmologists at a single large academic ophthalmology department were surveyed longitudinally before and after implementation of a new EHR system. The survey measured ophthalmologists’ attitudes toward implementation of a new EHR. Questions focused on satisfaction, efficiency, and documentation. All attending physicians (between 56 and 61 at various time points) in the University of Michigan Department of Ophthalmology and Visual Sciences were surveyed. We plotted positive responses to survey questions and assessed whether perceptions followed a J-curve with an initial decrease followed by an increase surpassing pre-implementation levels.Results Survey responses were received from 32 (52%) ophthalmologists pre-implementation, and 28 (46%) at 3 months, 35 (57%) at 7 months, 40 (71%) at 13 months and 39 (67%) at 24 months post-implementation. After EHR implementation respondents were more likely to express concerns about their ability to create high-quality documentation (p<0.01) and the impact of an electronic health record on meaningful patient interaction (p<0.01). Physicians did not report a significant change in the amount of time spent documenting outside of regular clinical work hours (p=0.54) or on their clinic efficiency and workflow (p=0.97). There was no significant change in overall job satisfaction during the study period (p=0.69). We did not observe a J-curve for any of the survey responses analyzed.Conclusions As ophthalmology practices continue to transition to EHRs, adapting them to their specific culture and needs is important to maintain efficiency and user satisfaction. This study identifies areas of concern to ophthalmologists that may be addressed through education of physicians and customization of software as other practices move forward with EHR implementation.Citation: Ehrlich JR, Michelotti M, Blachley TS, Zheng K, Couper MP, Greenberg GM, Kileny S, Branford GL, Hanauer DA, Weizer JS. A two-year longitudinal assessment of ophthalmologists’ perceptions after implementing an electronic health record system.


  • Baerveldt 250 mm2 Glaucoma Drainage Devices in Eyes With Preexisting Scleral Buckles

    by Linda Zhang, Taylor S. Blachley, Jennifer S. Weizer

    To evaluate eyes with preexisting scleral buckles (SBs) that underwent placement of a 250 mm Baerveldt glaucoma drainage device (GDD). Records of all patients with a preexisting SB who underwent 250 mm Baerveldt GDD placement at the Kellogg Eye Center between January 1, 2005 and September 30, 2012 were reviewed. Outcome measures included visual acuity (VA), intraocular pressure (IOP), and number of glaucoma medications prescribed. Seventeen eyes of 17 patients were analyzed. Mean follow-up was 23.9 months. Twelve eyes (70.6%) achieved successful control of IOP (<22 mm Hg, not requiring additional IOP reduction procedures, and no devastating complications). Preoperatively, mean IOP was 25.5 mm Hg, mean number of glaucoma medications was 3.5, and mean logMAR VA was 1.1 (Snellen equivalent 20/200). At 1 and 2 years postoperatively, mean IOP was 9.2 and 8.8 mm Hg (P<0.001), and mean number of glaucoma medications was 0.9 and 0.3 (P<0.001), respectively. There were no statistically significant changes in logMAR VA at 1 and 2 years postoperatively (P=0.45 and 0.99, respectively). Complications included conjunctival dehiscence (4 eyes, 24%), wound leak (2 eyes, 12%), tube and plate exposure requiring removal of drainage device (2 eyes, 12%), phthisis (2 eyes, 12%), and hemorrhagic choroidal detachment (1 eye, 6%). In eyes with preexisting SBs, the Baerveldt 250 mm GDD effectively lowers IOP and reduces the number of glaucoma medications. Complications related to conjunctival dehiscence are not uncommon in these eyes with significantly scarred conjunctiva.


  • Subsequent Receipt of Interventions for Glaucoma Among a Nationwide Sample of Patients Who Underwent Laser Peripheral Iridotomy

    by Surbhi Bansal, S. Asha Balakrishnan, Taylor Blachley, Jennifer S. Weizer, Paul P. Lee, Joshua D. Stein